ILIAS Biologics signed an MOU with HK inno.N for joint research to develop new biomedicine candidates on the 27th of May.

With this MOU, the two companies plan to collaborate - to discover and develop new drug candidates using exosomes, known as the next game-changer in the drug delivery system.

The MOU raises expectations on the synergy of ILIAS's versatile exosome platform technologies with enormous expandability and HK inno.N's extensive new drug development know-how.

Please find the link below for the detail.

HK이노엔, 일리아스와 '엑소좀' 신약 "공동연구 MOU" - 바이오스펙테이터 (biospectator.com)